Eterna Therapeutics Inc. Common Stock ERNA · Stock Open Eterna Therapeutics Inc. Common Stock in new tab
Eterna Therapeutics Inc. Common Stock Analysis (ERNA)
Is Eterna Therapeutics Inc. Common Stock a good investment? Eterna Therapeutics Inc. Common Stock (ERNA) is currently trading at 3.89 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.01. This relatively low multiple may signal that Eterna Therapeutics Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Eterna Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 6, 2026. The market consensus estimate for Forward EPS is -9.60.
Investor FAQ
Does Eterna Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Eterna Therapeutics Inc. Common Stock?
Eterna Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 6, 2026. The company currently has a trailing EPS of -0.39.
Company Profile
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| March 26, 2021 | 1:2 |
| Oct. 17, 2022 | 1:20 |
| June 12, 2025 | 1:15 |
| May 4, 2026 | 1:25 |
Community Discussion